Medtronic plc 's MDT brain therapy business gets a boost with the recent FDA approval for the company's latest Deep Brain Stimulation (DBS) Clinician Programmer and ActivaProgramming Application. This ...

Medtronic recently announced that the U.S. Food and Drug Administration (FDA) has approved its Deep Brain Stimulation (DBS) Clinician Programmer and Activa Programming Application. Medtronic’s DBS ...

Medical tech company Medtronic has just landed FDA clearance on its Deep Brain Stimulation (DBS) Clinical Programmer and ActivaProgramming application. "This marks a new era of innovation from the ...

DUBLIN and SAN JOSE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced the U.S. launch of its advanced Patient Programmer technology for Deep Brain Stimulation (DBS) ...

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever GALWAY, Ireland, Feb. 24, 2025 ...

This First-of-its-Kind Directional Lead Combines the Benefits of Directionality with the Power of Sensing DUBLIN, March 22, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical ...

Medtronic ($MDT) has earned a CE mark for its SureTune2 software. The tech offers physicians patient-specific visualizations which help them to “tune” a patient ...

At Samsung Developer Conference 2019 today, Medtronic and Samsung showed off a Galaxy smartphone app, Patient Programmer, that allows patients to manage their own therapy for Parkinson’s disease.

The medtech giant has begun rolling out its therapy in the U.S., with the treatment of its first commercially implanted patient after receiving a recent premarket approval from the FDA. The therapy ...

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...